Product News

Share this article:

FDA has approved Sanofi-Aventis's Nasacort AQ for use in children aged two to five years old. The indication is for nasal symptoms associated with perennial allergic rhinitis.

 The FDA will conduct trials to establish the safety of Teva's generic version of GlaxoSmithKline's Wellbutrin XL. The review was prompted by patients complaining of side effects after switching from the brand to the generic.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Agency Gallery

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters